CTRI/2017/10/010050
Recruiting
未知
Borderline resectable pancreatic tumors: outcomes of multimodality approach
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Borderline resectable pancreatic tumors
- Sponsor
- Tata Memorial Hospital
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Radiologically defined borderline resectable pancreatic tumors
Exclusion Criteria
- •1\) Metastatic tumors
- •2\) PS 2 and above
- •3\) Liver and renal function criteria precluding any form of neoadjuvant treatment
- •4\) Previous history of any malignancy, cardiac or respiratory disorder, which precludes any form of neoadjuvant treatment
- •5\) Previously treated patient
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Improving preoperative staging in patients with locally resectable pancreatic cancer – a randomised controlled trial comparing 12 month recurrence rate of patients managed with standard preoperative assessment of liver metastases, contrast enhanced CT( computed tomography) to preoperative assessment of liver metastases with Primovist (liver specific contrast) MRI ( magnetic resonance imaging )pancreas adenocarcinomaCancer - PancreaticACTRN12614001287628jai seema bagia24
Recruiting
Not Applicable
Outcomes of pancreatic cystsPancreatic cysts, pancreatic cystic neoplasms, IPMNPancreascystenNL-OMON29340Academic Medical Center600
Recruiting
Not Applicable
Pancreatic Locally advanced Irresectable Cancer AblatioN (PELICAN trial)Locally advanced pancreatic cancernon-resectabel pancreatic tumor10017998NL-OMON56404Amsterdam UMC174
Recruiting
Phase 1
Successful rate of creation pancreatic cancer organoids by EUS-guided fine needle biopsy samplingpancreatic mass suspected pancreatic cancerorganoid,pancreas,pancreatic cancer,EUS,FNBTCTR20200827007none28
Active, not recruiting
Phase 1
A study in patients with borderline unresectable pancreatic cancer, where Abraxane and Gemcitabine will be administered with the goal of shrinking tumours to make them operable.ocally advanced pancreatic cancerMedDRA version: 17.0 Level: LLT Classification code 10033606 Term: Pancreatic cancer non-resectable System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-004200-19-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge9